MedPath

Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma

Phase 2
Conditions
Brain and Central Nervous System Tumors
Registration Number
NCT00514397
Lead Sponsor
Children's Cancer and Leukaemia Group
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temozolomide together with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving temozolomide together with radiation therapy works in treating young patients with pontine glioma.

Detailed Description

OBJECTIVES:

Primary

* To evaluate the time to death in patients with newly diagnosed diffuse pontine gliomas, when treated with the combination of concomitant low-dose oral temozolomide and radiotherapy, followed by up to 12 months of maintenance therapy with extended low-dose temozolomide.

* To assess the quality of life of patients with diffuse pontine gliomas during and after treatment.

Secondary

* To evaluate the time to tumor progression in patients with newly diagnosed diffuse pontine gliomas, when treated with the combination of concomitant low-dose oral temozolomide and radiotherapy, followed by up to 12 months of maintenance therapy with extended low-dose temozolomide.

* To evaluate and document toxicities from the administration of temozolomide combined with radiotherapy and to further study any toxicities associated with the chronic administration of the extended low-dose temozolomide schedule in this population group.

* To document radiological response to the above treatment with MR imaging and, where available, functional imaging.

OUTLINE: This is a multicenter study.

* Chemoradiotherapy: Patients receive oral temozolomide once daily for 6 weeks (7 days per week) with concurrent radiotherapy (5 days per week).

Patients without evidence of disease progression proceed to maintenance therapy beginning at least 4 weeks after completion of radiotherapy.

* Maintenance therapy: Patients receive oral temozolomide daily on days 1-21. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed prior to chemoradiotherapy and prior to course 1 of adjuvant temozolomide and prior to every 3 subsequent courses of adjuvant temozolomide.

After completion of study therapy, patients are followed every 8 weeks.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
43
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival
Quality of life including health status, behavior, and the subjective experience using HUI and SDQ methods
Secondary Outcome Measures
NameTimeMethod
Toxicity, steroid usage, and radiological response
Adverse events, including abnormal laboratory parameters, as assessed by CTC criteria

Trial Locations

Locations (20)

Leeds Cancer Centre at St. James's University Hospital

🇬🇧

Leeds, England, United Kingdom

Addenbrooke's Hospital

🇬🇧

Cambridge, England, United Kingdom

Great Ormond Street Hospital for Children

🇬🇧

London, England, United Kingdom

Royal Hospital for Sick Children

🇬🇧

Glasgow, Scotland, United Kingdom

Bristol Royal Hospital for Children

🇬🇧

Bristol, England, United Kingdom

Royal Liverpool Children's Hospital, Alder Hey

🇬🇧

Liverpool, England, United Kingdom

Our Lady's Hospital for Sick Children Crumlin

🇮🇪

Dublin, Ireland

Birmingham Children's Hospital

🇬🇧

Birmingham, England, United Kingdom

Leicester Royal Infirmary

🇬🇧

Leicester, England, United Kingdom

Royal Manchester Children's Hospital

🇬🇧

Manchester, England, United Kingdom

Sir James Spence Institute of Child Health at Royal Victoria Infirmary

🇬🇧

Newcastle-Upon-Tyne, England, United Kingdom

Queen's Medical Centre

🇬🇧

Nottingham, England, United Kingdom

University College Hospital

🇬🇧

London, England, United Kingdom

Southampton General Hospital

🇬🇧

Southampton, England, United Kingdom

Children's Hospital - Sheffield

🇬🇧

Sheffield, England, United Kingdom

Oxford Radcliffe Hospital

🇬🇧

Oxford, England, United Kingdom

Royal Marsden - Surrey

🇬🇧

Sutton, England, United Kingdom

Royal Belfast Hospital for Sick Children

🇬🇧

Belfast, Northern Ireland, United Kingdom

Royal Aberdeen Children's Hospital

🇬🇧

Aberdeen, Scotland, United Kingdom

Childrens Hospital for Wales

🇬🇧

Cardiff, Wales, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath